To evaluate the efficacy (in terms of change HbA1c from baseline to endpoint) and safety (in
terms of adverse events, clinical chemistry, lipids, hematology) of insulin glulisine (HMR
1964) in subjects with type I diabetes mellitus To evaluate the change in HbA1c at week 26,
blood/glucose parameters, hypoglycemia, insulin dose in subjects with type I diabetes
mellitus receiving HMR 1964 and insulin glargine.